Overview

Better immunotherapies to increase the potential for cancer cures

Agenus is a clinical-stage biopharmaceutical company that discovers, manufactures, and develops immunotherapies for cancer. Our portfolio consists of bio-engineered therapies designed to activate the body’s own defenses in order to fight cancer. These therapies are optimized through an integrated, proprietary active learning platform designed to deliver better drugs, optimized combinations, and predictive biomarkers to address critical unmet needs in cancer.

Building a leadership position in cancer immunotherapy

Active learning and prediction R&D platform uncovers the biology behind clinical responses to (i) identify response prediction biomarkers and (ii) build pipeline to address resistance pathways

Learn more about VISION 

12 clinical-stage programs supported by vertically integrated internal capabilities spanning discovery, manufacturing, clinical, and commercial.

Learn more about Agenus’ manufacturing capabilities

Learn more about Agenus’ clinical capabilities

Track record of collaborations with commercial oncology leaders (BMS, Merck, Gilead, GSK, Incyte), generating value and speed in clinical development.

Learn more about Agenus’ partnerships

Active learning and prediction R&D platform uncovers the biology behind clinical responses to (i) identify response prediction biomarkers and (ii) build pipeline to address resistance pathways

Learn more about VISION 

12 clinical-stage programs supported by vertically integrated internal capabilities spanning discovery, manufacturing, clinical, and commercial.

Learn more about Agenus’ manufacturing capabilities

Learn more about Agenus’ clinical capabilities

Track record of collaborations with commercial oncology leaders (BMS, Merck, Gilead, GSK, Incyte), generating value and speed in clinical development.

Learn more about Agenus’ partnerships

Our partnerships include:

Gilead

In 2018, Agenus and Gilead entered into a partnership to develop novel immuno-oncology therapies. Gilead currently has an exclusive option to license AGEN2373, a conditionally active CD137 agonist. AGEN2373 is being evaluated in a Phase 1b combination study with botensilimab (Fc-enhanced anti-CTLA-4), in melanoma patients who had relapsed on, or were refractory to, prior anti-PD-1 therapy. Agenus has received $177.5M in upfront and achieved milestone payments, and is eligible for up to $570M in potential option fees and future milestone payments, as well as royalties on worldwide product sales up to the mid-teens. Agenus retains the right to opt-in to share Gilead’s development and commercialization costs in the United States in exchange for a 50:50 profit share and US co-commercialization rights.

Incyte

In 2015, Agenus and Incyte entered into a global alliance to develop checkpoint modulating antibodies for cancer treatment.  The collaboration has generated four clinical-stage programs directed against GITR, OX40, LAG-3 and TIM-3.  Agenus is eligible for up to $500M in potential development, regulatory and commercial milestone payments as well as royalties on worldwide product sales up to the low-double digits.

Bristol Myers Squibb

In 2021, Agenus and Bristol Myers Squibb entered into a global license agreement for Agenus’ anti-TIGIT bi-specific antibody, BMS-986442 (AGEN1777). BMS-986442 is being evaluated in a Phase I study, and Bristol Myers Squibb intends to advance the research and development of BMS-986442 in high priority tumor indications including non-small cell lung cancer. Agenus has received $220M in upfront and achieved milestone payments, and is eligible for up to $1.34B in potential future milestone payments, as well as royalties on worldwide product sales up to the mid-teens. Agenus retains options to conduct clinical studies under the development plan, to conduct combination studies with certain other Agenus pipeline assets, and to co-promote BMS-986442 in the US upon commercialization.

Betta Pharmaceuticals

In 2020, Agenus and Betta Pharmaceuticals entered into a license agreement for balstilimab (anti-PD-1 antibody) and zalifrelimab (anti-CTLA-4 antibody) in Greater China.  Agenus is eligible for up to $100M in potential milestone payments, as well as royalties on product sales up to the low-twenties.

Urogen Pharma

In 2019, Agenus and UroGen entered into a license agreement for the use of Agenus’ anti-CTLA-4 antibody, zalifrelumab, with UroGen’s sustained release technology for intravesical delivery in patients with urinary tract cancers.   Agenus is eligible for up to $200M in potential milestone payments, as well as royalties on product sales up to the low-twenties.

GSK

Agenus licensed QS-21 Stimulon to GSK for use in its vaccines, including Shingrix and Mosquirix.  The FDA granted approval to GSK’s Shingrix in 2017, and Shingrix generated over $2 billion in net sales for GSK in 2021.  In 2018, Agenus and HealthCare Royalty Partners announced a $230 million non-dilutive royalty transaction on sales of GSK’s QS-21 containing vaccines.  Agenus is eligible for up to $25M in potential milestone payments.

Merck

In 2014, Agenus and Merck entered into a collaboration and license agreement to develop checkpoint modulating antibodies for cancer treatment.  The collaboration has resulted in the generation of MK-4830, an anti-ILT4 antibody that Merck is developing in multiple oncology indications.  Agenus is eligible for up to $85M in potential development, regulatory and commercial milestone payments as well as royalties on worldwide product sales.

Join Us

We have brought together top talent and expertise to advance our mission, building a team of over 400 employees across our offices in the US and Europe.